Molecular mechanisms of ferroptosis and their involvement in brain diseases

• Published in: Pharmacology & therapeutics (Oxford) Vol. 244; p. 108373
• Main Authors: Costa, Inês, Barbosa, Daniel José, Benfeito, Sofia, Silva, Vera, Chavarria, Daniel, Borges, Fernanda, Remião, Fernando, Silva, Renata
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.04.2023
• Subjects: Brain diseases; Brain Diseases - drug therapy; Cell Death - physiology; Ferroptosis; Ferroptosis inducers, Ferroptosis inhibitors; Ferroptosis mechanisms; Humans; Lipid Peroxidation; Reactive Oxygen Species - metabolism; APP; GTP; RAS; mHtt; Ferroptosis mechanisms; TRAP; COMT; DFO; MPP; Sat1; CTF-β; I/R; CTF-α; DFP; 4-HNE; BACE-1; TfR1; FDXR; CHAC1; GMB; BSO; AA; AD; L-OOH; EAE; CYBB; ACSL4; i.p; LOO; PPARγ; FIN56; POR; RCD; ChEs; PDAC; ARE; CoA; LOX; SCO2; Lip-1; AMPK; FTH; DPI; β-ME; RTA; ATF4; FTL; FDA; CNS; RSL5; ACACA; RSL3; FSP1; DPP4; EeAChE; NADH; ΔΨm; Nrf2; NH2TP; COX2; HMOX1; ReN; SFN; SN; Fer-1; AdA; MCAO; GSSG; ACD; FRDA; MSO; CGL; SOD; MAO-B; ICH; DHFR; LIP; NFTs; ETC; Keap1; VDAC; FSP1KO; MPTP; ATP; RNA; DMT1; ALS; 6-OHDA; MDA; Cp; DBM; GPX; 15-LOX; Aβ; NF-κB; HEPH; SPR; AIFM2; IREs; Brain diseases; NIH-MLSMR; GPX4; PUFA; MS; iPSC; NCOA4; HCC; PKC; TBARS; BH4; MEF; TCA; NeuN; SQS; α-syn; NOX; TDP-43; ROS; GABA; NAPQI; FXN; EqBChE; αKG; NADPH; BECN1; DDC; GLS1; FPN; GLS2; CoQ10; FPP; Ferroptosis; HTT; mRNA; PTGS2; PTS; LDH; CBS; GCLC/GCLM; L-Cys; L-OH; GSH; GCH1; GSS; IRP1; HMG-CoA; IRP2; GR; Ferroptosis inducers, Ferroptosis inhibitors; Mutp53; P53; NAC; NCCD; PD; 73Q; PE-OOH; PE; DNA; LPCAT3; HD; shACSL4
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2023.108373

Ferroptosis is a type of regulated cell death characterized by intracellular accumulation of iron and reactive oxygen species, inhibition of system Xc-, glutathione depletion, nicotinamide adenine dinucleotide phosphate oxidation and lipid peroxidation. Since its discovery and characterization in 2012, many efforts have been made to reveal the underlying mechanisms, modulating compounds, and its involvement in disease pathways. Ferroptosis inducers include erastin, sorafenib, sulfasalazine and glutamate, which, by inhibiting system Xc-, prevent the import of cysteine into the cells. RSL3, statins, Ml162 and Ml210 induce ferroptosis by inhibiting glutathione peroxidase 4 (GPX4), which is responsible for preventing the formation of lipid peroxides, and FIN56 and withaferin trigger GPX4 degradation. On the other side, ferroptosis inhibitors include ferrostatin-1, liproxstatin-1, α-tocopherol, zileuton, FSP1, CoQ10 and BH4, which interrupt the lipid peroxidation cascade. Additionally, deferoxamine, deferiprone and N-acetylcysteine, by targeting other cellular pathways, have also been classified as ferroptosis inhibitors. Increased evidence has established the involvement of ferroptosis in distinct brain diseases, including Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, multiple sclerosis, and Friedreich's ataxia. Thus, a deep understanding of how ferroptosis contributes to these diseases, and how it can be modulated, can open a new window of opportunities for novel therapeutic strategies and targets. Other studies have shown a sensitivity of cancer cells with mutated RAS to ferroptosis induction and that chemotherapeutic agents and ferroptosis inducers synergize in tumor treatment. Thus, it is tempting to consider that ferroptosis may arise as a target mechanistic pathway for the treatment of brain tumors. Therefore, this work provides an up-to-date review on the molecular and cellular mechanisms of ferroptosis and their involvement in brain diseases. In addition, information on the main ferroptosis inducers and inhibitors and their molecular targets is also provided.